On September 9, 2020 Surface Oncology (Nasdaq:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, reported that Jeff Goater, its chief executive officer, and Robert Ross, M.D., its chief medical officer, will present at the upcoming Robert W. Baird Global Healthcare Conference, discussing Surface Oncology’s lead programs, SRF617 (targeting CD39) and SRF388 (targeting IL-27) as well as Surface’s emerging pre-clinical pipeline, highlighted by SRF813 (targeting CD112R, aka PVRIG) (Press release, Surface Oncology, SEP 9, 2020, View Source [SID1234564820]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be in the format of a fireside chat and take place virtually on Thursday September 10, 2020 at 1:25 pm EDT.